- Home
- ENVX vs CPRX Comparison
ENVX vs CPRX Comparison
Compare ENVX & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVX
- CPRX
- Stock Information
- Founded
- ENVX 2006
- CPRX 2002
- Country
- ENVX United States
- CPRX United States
- Employees
- ENVX N/A
- CPRX N/A
- Industry
- ENVX Industrial Machinery/Components
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ENVX Miscellaneous
- CPRX Health Care
- Exchange
- ENVX Nasdaq
- CPRX Nasdaq
- Market Cap
- ENVX 2.2B
- CPRX 2.6B
- IPO Year
- ENVX N/A
- CPRX 2006
- Fundamental
- Price
- ENVX $10.21
- CPRX $20.23
- Analyst Decision
- ENVX Buy
- CPRX Strong Buy
- Analyst Count
- ENVX 11
- CPRX 5
- Target Price
- ENVX $19.82
- CPRX $33.20
- AVG Volume (30 Days)
- ENVX 8.3M
- CPRX 1.4M
- Earning Date
- ENVX 07-31-2025
- CPRX 08-06-2025
- Dividend Yield
- ENVX N/A
- CPRX N/A
- EPS Growth
- ENVX N/A
- CPRX 183.96
- EPS
- ENVX N/A
- CPRX 1.65
- Revenue
- ENVX $26,600,000.00
- CPRX $558,499,000.00
- Revenue This Year
- ENVX $46.94
- CPRX $16.37
- Revenue Next Year
- ENVX $229.44
- CPRX $8.80
- P/E Ratio
- ENVX N/A
- CPRX $12.28
- Revenue Growth
- ENVX 60.04
- CPRX 28.55
- 52 Week Low
- ENVX $4.61
- CPRX $19.00
- 52 Week High
- ENVX $16.49
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- ENVX 35.35
- CPRX 42.27
- Support Level
- ENVX $10.53
- CPRX $19.82
- Resistance Level
- ENVX $11.16
- CPRX $20.51
- Average True Range (ATR)
- ENVX 0.74
- CPRX 0.72
- MACD
- ENVX -0.36
- CPRX -0.04
- Stochastic Oscillator
- ENVX 5.67
- CPRX 31.95
About ENVX Enovix Corporation
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).